Erectile dysfunction: an underdiagnosed condition associated with multiple risk factors

Area of Science:

• Urology
• Andrology
• Epidemiology

Background:

• Erectile dysfunction (ED) is a prevalent condition impacting quality of life, with prevalence increasing with age and comorbidities like hypertension, diabetes, and depression.
• The MALES study, a large-scale epidemiological survey, investigated ED prevalence across eight countries, including 27,839 patients.
• The study also reviews the association between lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), and ED, and the impact of BPH treatments on sexual function.

Discussion:

• Preliminary findings from the MALES II study indicate a significant effect on patient behavior regarding seeking and adhering to treatment for ED with sildenafil.
• Exploration of reasons for discontinuation of oral phosphodiesterase-5 inhibitors (PDE5i) for long-term ED management is discussed.
• The interplay between LUTS, BPH, and ED suggests a common pathophysiology and potential for integrated treatment approaches.

Key Insights:

• ED prevalence is significantly influenced by age and common chronic health conditions.
• The MALES study provides extensive epidemiological data on ED across diverse populations.
• Sildenafil treatment in the MALES II study shows promising effects on treatment-seeking behavior and adherence.

Outlook:

• Further research into the long-term adherence challenges with PDE5 inhibitors is warranted.
• Investigating the combined management of LUTS/BPH and ED may improve patient outcomes.
• Understanding patient-reported reasons for treatment discontinuation is crucial for optimizing ED management strategies.